Study Shows 80% Long-Term Survival Results of Low Dose CT Lung Cancer Screening

A 20-year study conducted by the global I-ELCAP team confirms that low dose CT lung cancer screening has an outstanding 80% long-term survival rate. In those 20 years, I-ELCAP has supported around 90,000 lung screening participants, almost 300 publications and numerous international study confirmations. The I-ELCAP lung screening protocol represents a major advance in the war on cancer. To read more, visit https://www.auntminnie.com/index.aspx?sec=sup&sub=cto&pag=dis&ItemID=138686

Contact Accumetra at info@accumetra.com to learn how to deploy ScreeningPLUS, the commercially available version of the I-ELCAP lung cancer screening management system, at your institution.

Make it stand out

Whatever it is, the way you tell your story online can make all the difference.

Previous
Previous

Accumetra Presents a New Lung Nodule Measurement Approach at the 2023 I-ELCAP Meeting in Verona

Next
Next

Accumetra and RSNA/QIBA Launch QIBA Conformance Certification Services at RSNA 2018